Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
- 1 February 2011
- journal article
- review article
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (2), 129-146
- https://doi.org/10.1111/j.1365-4632.2010.04791.x
Abstract
The last decade in oncology has been highlighted by the emergence of novel, highly specific anti‐cancer agents, targeting a variety of molecular structures and able to inhibit aberrantly activated oncogenic pathways. Epidermal growth factor receptor inhibitors (EGFRIs) represent one type of such “targeted” agents. Their use made treatment more tolerable and resulted in significant reduction of systemic adverse effects. However, EGFRIs are associated with toxicities affecting the skin and adnexal structures, and mucosal surfaces that affect the majority of treated patients. Significant dermatologic toxicities have changed the role and involvement of dermatologists in their care. It is essential to be familiar with these adverse effects, potential complications, long‐term sequelae, and available effective treatment strategies in order to appropriately manage these patients. This review will describe the clinical presentation, histopathology, underlying mechanisms, and management options, emphasizing evidence‐based approaches.Keywords
This publication has 67 references indexed in Scilit:
- Skin toxicities of targeted therapiesEuropean Journal Of Cancer, 2009
- Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current SmokersJournal of Clinical Oncology, 2009
- Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147Oncology, 2008
- Severe skin reaction secondary to concomitant radiotherapy plus cetuximabRadiation Oncology, 2008
- Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey ResultsOncology, 2007
- Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical ManagementThe Oncologist, 2007
- Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patientsJournal of the American Academy of Dermatology, 2006
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinibJournal of the American Academy of Dermatology, 2006
- HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management ForumThe Oncologist, 2005
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005